ml 7 has been researched along with Disease Models, Animal in 16 studies
ML-7 : An N-sulfonyldiazepane resullting from the formal condensation of 5-iodo-1-naphthylsulfonic acid with one of the nitrogens of 1,4-diazepane. It is a selective inhibitor of myosin light chain kinase (EC 2.7.11.18).
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "HFD-fed rabbits showed typical atheromatous lesions and endothelial hyperpermeability, and these lesions could be partly reversed following ML7 therapy." | 1.56 | Myosin light chain kinase inhibitor ML7 improves vascular endothelial dysfunction and permeability via the mitogen-activated protein kinase pathway in a rabbit model of atherosclerosis. ( Ding, J; Ding, Y; Gui, S; Li, L; Li, Z; Meng, S; Wang, D; Wang, Y; Wei, W; Zhou, Q; Zhu, H, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 10 (62.50) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, RL | 1 |
| Kahraman, M | 1 |
| Prins, TJ | 1 |
| Beaver, Y | 1 |
| Cook, TG | 1 |
| Cramp, J | 1 |
| Cayanan, CS | 1 |
| Gardiner, EM | 1 |
| McLaughlin, MA | 1 |
| Clark, AF | 1 |
| Hellberg, MR | 1 |
| Shiau, AK | 1 |
| Noble, SA | 1 |
| Borchardt, AJ | 1 |
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Sharma, U | 1 |
| Olson, RK | 1 |
| Erhart, FN | 1 |
| Zhang, L | 2 |
| Meng, J | 1 |
| Segura, B | 1 |
| Banerjee, S | 1 |
| Sharma, M | 1 |
| Saluja, AK | 1 |
| Ramakrishnan, S | 1 |
| Abreu, MT | 1 |
| Roy, S | 1 |
| Ding, J | 1 |
| Li, Z | 1 |
| Li, L | 1 |
| Ding, Y | 1 |
| Wang, D | 1 |
| Meng, S | 1 |
| Zhou, Q | 2 |
| Gui, S | 1 |
| Wei, W | 1 |
| Zhu, H | 2 |
| Wang, Y | 2 |
| Huang, C | 1 |
| Zhang, Z | 1 |
| Wang, L | 1 |
| Liu, J | 1 |
| Gong, X | 1 |
| Zhang, C | 1 |
| Moussaoui, N | 1 |
| Braniste, V | 1 |
| Ait-Belgnaoui, A | 1 |
| Gabanou, M | 1 |
| Sekkal, S | 1 |
| Olier, M | 1 |
| Théodorou, V | 2 |
| Martin, PG | 1 |
| Houdeau, E | 1 |
| Zhang, HF | 1 |
| Li, TB | 1 |
| Liu, B | 1 |
| Lou, Z | 1 |
| Zhang, JJ | 1 |
| Peng, JJ | 1 |
| Zhang, XJ | 1 |
| Ma, QL | 1 |
| Peng, J | 1 |
| Luo, XJ | 1 |
| Zhang, Y | 1 |
| Li, J | 1 |
| Chi, Y | 1 |
| Li, M | 1 |
| Pan, X | 1 |
| Zhang, Q | 1 |
| He, X | 1 |
| Liu, Y | 1 |
| Cheng, X | 1 |
| Wang, X | 1 |
| Wan, Y | 1 |
| Bai, JW | 1 |
| Deng, WW | 1 |
| Zhang, J | 1 |
| Xu, SM | 1 |
| Zhang, DX | 1 |
| Conlin, VS | 1 |
| Wu, X | 1 |
| Nguyen, C | 1 |
| Dai, C | 1 |
| Vallance, BA | 1 |
| Buchan, AM | 1 |
| Boyer, L | 1 |
| Jacobson, K | 1 |
| Luh, C | 1 |
| Kuhlmann, CR | 1 |
| Ackermann, B | 1 |
| Timaru-Kast, R | 1 |
| Luhmann, HJ | 1 |
| Behl, C | 1 |
| Werner, C | 1 |
| Engelhard, K | 1 |
| Thal, SC | 1 |
| Ouyang, Y | 1 |
| Nakao, A | 1 |
| Han, D | 1 |
| Al-Sadi, R | 1 |
| Guo, S | 1 |
| Dokladny, K | 1 |
| Smith, MA | 1 |
| Ye, D | 1 |
| Kaza, A | 1 |
| Watterson, DM | 1 |
| Ma, TY | 1 |
| Eutamene, H | 1 |
| Schmidlin, F | 1 |
| Tondereau, V | 1 |
| Garcia-Villar, R | 1 |
| Salvador-Cartier, C | 1 |
| Chovet, M | 1 |
| Bertrand, C | 1 |
| Bueno, L | 1 |
16 other studies available for ml 7 and Disease Models, Animal
| Article | Year |
|---|---|
Benzothiophene containing Rho kinase inhibitors: Efficacy in an animal model of glaucoma.
Topics: Animals; Disease Models, Animal; Glaucoma; Haplorhini; HeLa Cells; Humans; Intraocular Pressure; Ocu | 2010 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Prescription Opioids induce Gut Dysbiosis and Exacerbate Colitis in a Murine Model of Inflammatory Bowel Disease.
Topics: Analgesics, Opioid; Animals; Azepines; Disease Models, Animal; Dysbiosis; Enzyme Inhibitors; Gastroi | 2020 |
Myosin light chain kinase inhibitor ML7 improves vascular endothelial dysfunction and permeability via the mitogen-activated protein kinase pathway in a rabbit model of atherosclerosis.
Topics: Animals; Aorta, Thoracic; Atherosclerosis; Azepines; Diet, High-Fat; Disease Models, Animal; Endothe | 2020 |
ML-7 attenuates airway inflammation and remodeling via inhibiting the secretion of Th2 cytokines in mice model of asthma.
Topics: Airway Remodeling; Animals; Asthma; Azepines; Cytokines; Disease Models, Animal; Female; Inflammatio | 2018 |
Changes in intestinal glucocorticoid sensitivity in early life shape the risk of epithelial barrier defect in maternal-deprived rats.
Topics: Analysis of Variance; Animals; Azepines; Bacterial Translocation; Colon; Colony-Forming Units Assay; | 2014 |
Inhibition of myosin light chain kinase reduces NADPH oxidase-mediated oxidative injury in rat brain following cerebral ischemia/reperfusion.
Topics: Animals; Azepines; Brain; Brain Ischemia; Disease Models, Animal; Hydrogen Peroxide; Male; Membrane | 2015 |
[Myosin light chain kinase involved in change of intestinal mucosal barrier function in nonalcoholic steatohepatitis mice model].
Topics: Animals; Azepines; Disease Models, Animal; Fatty Liver; Interleukin-6; Intestinal Mucosa; Intestines | 2015 |
Myosin light chain kinase inhibitor ML7 improves vascular endothelial dysfunction via tight junction regulation in a rabbit model of atherosclerosis.
Topics: Animals; Atherosclerosis; Azepines; Diet, High-Fat; Disease Models, Animal; Endothelium, Vascular; L | 2015 |
[Protective effect of myosin light-chain kinase inhibitor on acute lung injury].
Topics: Acute Lung Injury; Animals; Azepines; Cells, Cultured; Disease Models, Animal; Endothelial Cells; Fe | 2009 |
Vasoactive intestinal peptide ameliorates intestinal barrier disruption associated with Citrobacter rodentium-induced colitis.
Topics: Animals; Anti-Inflammatory Agents; Azepines; Bacterial Adhesion; Bacterial Translocation; Caco-2 Cel | 2009 |
Inhibition of myosin light chain kinase reduces brain edema formation after traumatic brain injury.
Topics: Animals; Azepines; Blood-Brain Barrier; Brain Edema; Brain Injuries; Constriction; Disease Models, A | 2010 |
Transforming growth factor-β1 promotes nasal mucosal mast cell chemotaxis in murine experimental allergic rhinitis.
Topics: ADP Ribose Transferases; Animals; Azepines; Botulinum Toxins; Chemotaxis; Disease Models, Animal; Di | 2012 |
Mechanism of interleukin-1β induced-increase in mouse intestinal permeability in vivo.
Topics: Animals; Azepines; Caco-2 Cells; Crohn Disease; Dextrans; Disease Models, Animal; Enterocytes; Human | 2012 |
LPS-induced lung inflammation is linked to increased epithelial permeability: role of MLCK.
Topics: Animals; Azepines; Cells, Cultured; Disease Models, Animal; Enzyme Inhibitors; Humans; Lipopolysacch | 2005 |